Drug Interaction Between Zyprexa (Olanzapine) and Cobenfy (Xanomeline-Trospium)

Mechanism of Concern

The American College of Clinical Pharmacology recommends caution when combining olanzapine and xanomeline-trospium due to overlapping anticholinergic effects, additive sedation risks, and the potential for excessive CNS depression 1, 2.
The National Comprehensive Cancer Network suggests that olanzapine has significant anticholinergic activity through acetylcholine-muscarine receptor antagonism, causing common side effects including dry mouth, constipation, and cognitive impairment 1.

The American Academy of Child and Adolescent Psychiatry recommends assessing baseline anticholinergic burden from all medications the patient is taking before initiating combination therapy 6.
The Mayo Clinic suggests obtaining baseline metabolic parameters, including weight, fasting glucose, and lipid panel, before starting combination therapy 4, 7.
The American College of Clinical Pharmacology recommends starting with reduced doses of both medications to minimize additive adverse effects, and titrating slowly with at least 1-2 week intervals between dose adjustments 3, 4.

The National Comprehensive Cancer Network recommends monitoring for excessive sedation at each dose adjustment and regularly thereafter, as well as assessing for anticholinergic toxicity, including constipation, urinary retention, dry mouth, blurred vision, confusion, and delirium 1, 2, 4.
The American Academy of Child and Adolescent Psychiatry suggests checking orthostatic vital signs as both medications can cause orthostatic hypotension 4, 6.

The American Geriatrics Society recommends exercising caution when using olanzapine in elderly patients due to increased mortality risk, and starting with a lower dose of 2.5 mg daily 1, 3.
The American Heart Association suggests avoiding the combination in patients with severe cardiovascular disease or those at high risk for QTc prolongation 4.

The American College of Clinical Pharmacology recommends never combining olanzapine with benzodiazepines if possible, as fatalities have been reported with olanzapine-benzodiazepine combinations at high doses 4, 5.
The American Academy of Neurology suggests avoiding the use of olanzapine in patients with Parkinson's disease or dementia with Lewy bodies due to severe sensitivity to anticholinergic effects and dopaminergic modulation 4.